Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company dedicated to developing precision oncology medicines. The company specializes in using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match patients with the oncology medicines most likely to work for them. This groundbreaking approach integrates drug-regulated global proteomics with intact tissue digital imaging to create drug-specific biomarker signatures, known as OncoSignature companion diagnostics, for identifying patient responders.
The company's leading candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2. This drug is currently in a potentially registrational Phase 2 trial and has received Fast Track designation from the FDA for investigating its use as monotherapy for patients with platinum-resistant ovarian or endometrial cancer. The ACR-368 OncoSignature test, which is pending regulatory approval, has shown promising results in preclinical studies and past third-party Phase 2 trials.
Additionally, Acrivon is advancing ACR-2316, a selective dual WEE1/PKMYT1 inhibitor designed using the AP3 platform. This candidate shows superior single-agent activity in preclinical studies compared to benchmark inhibitors. Acrivon plans to submit an IND for ACR-2316 in Q3 2024, with clinical study initiation expected in Q4 2024.
The company's AP3 platform not only aids in drug selection but also in rational drug design and optimization. It's engineered to measure drug effects on the tumor cell protein network, identifying resistance mechanisms and optimal drug combinations.
Recently, Acrivon has made significant strides, including FDA Breakthrough Device designation for its ACR-368 OncoSignature assay and a successful $130 million private placement financing to further fund its innovative pipeline and platform development. Acrivon's focus remains on leveraging its AP3 platform for the development of precision oncology drugs that address significant unmet medical needs, aiming to improve treatment outcomes for cancer patients worldwide.
For more updates and detailed financial information, visit Acrivon's investor relations page.
Acrivon Therapeutics (Nasdaq: ACRV) will present data on its AP3 platform at two scientific conferences: HUPO World Congress and EORTC-NCI-AACR Symposium. The presentations will showcase AP3's capabilities in drug discovery and clinical development.
Key highlights include:
- AP3-identified clinical biomarkers for ACR-368 led to a response-predictive OncoSignature assay, showing statistically significant prospective validation in an ongoing Phase 2b study.
- ACR-2316, a novel WEE1/PKMYT1 inhibitor, was optimized using AP3 to deliver superior single agent activity and complete tumor regression.
- AP3 enables overcoming challenges in biopharma, including biomarker discovery, resistance mechanism identification, and patient responder prediction.
The company will present posters on ACR-368 and ACR-2316 at both conferences, demonstrating AP3's impact on streamlined clinical development and drug design.
Acrivon Therapeutics (Nasdaq: ACRV), a clinical stage precision medicine company, announced the approval of equity awards under its 2023 Inducement Plan for certain employees. The awards, granted on October 15, 2024, consist of stock options to purchase a total of 61,950 shares of Acrivon common stock.
The stock options will vest according to the following schedule:
- 25% on the first anniversary of the first day of the month following each employee's effective employment date
- Additional 2.083% installments monthly thereafter
Vesting is subject to continued employment. The inducement grants were approved by Acrivon's Board of Directors in compliance with Nasdaq Rule 5635(c)(4) and serve as a material inducement to employment.
Acrivon Therapeutics (NASDAQ: ACRV) reported positive data from its ongoing Phase 2 trial of ACR-368 in endometrial cancer at ESMO. Key highlights include:
- 62.5% confirmed overall response rate in OncoSignature-positive patients
- Statistically significant segregation of responders (p-value = 0.009)
- Median duration of response not yet reached (~6 months at data cut-off)
- Endometrial cancer anticipated as first potential accelerated approval indication
Additionally, Acrivon announced FDA clearance of the IND for ACR-2316, with first-in-human dosing expected in Q4 2024. The company's AP3 Interactome platform is generating proprietary insights for drug development and patient selection.
Acrivon Therapeutics (Nasdaq: ACRV), a clinical stage precision medicine company, has announced its participation in the Cantor Global Healthcare Conference in New York. The company's president and CEO, Peter Blume-Jensen, M.D., Ph.D., will engage in a fireside chat on Tuesday, September 17, 2024, at 8:35 a.m. ET.
Acrivon utilizes its Acrivon Predictive Precision Proteomics (AP3) platform for drug candidate discovery and development, focusing on mechanistic matches to patients whose diseases are predicted to be sensitive to specific treatments. Interested parties can access a live webcast of the event through the company's investor relations website. A replay will be available shortly after the presentation.
Acrivon Therapeutics (Nasdaq: ACRV) announced a virtual investor event on September 14, 2024, to review positive Phase 2 clinical data of ACR-368 presented at ESMO and pipeline progress. The event will highlight:
1. Updated ACR-368 clinical data in endometrial cancer from the ongoing registrational intent Phase 2b study
2. Updates on lead assets ACR-368, ACR-2316, and the AP3 platform
3. Previous data showed a 50% confirmed response rate across ovarian and endometrial cancer patients
4. Enrollment for endometrial cancer patients is progressing ahead of schedule
5. The study represents the first potential approval opportunity for ACR-368
The ESMO poster presentation details and webcast information are provided in the announcement.
Acrivon Therapeutics (Nasdaq: ACRV) reported Q2 2024 financial results and business highlights. Key points include:
- Planned webcast in September 2024 during ESMO conference to update on clinical programs and AP3 platform progress
- Initial positive clinical data for ACR-368 showed 50% overall response rate in gynecological cancers
- On track to initiate Phase 1 study for ACR-2316 in Q4 2024
- Executed $130 million private placement financing
- Q2 2024 net loss of $18.8 million, compared to $13.9 million in Q2 2023
- Cash position of $220.4 million, expected to fund operations into second half of 2026
Acrivon Therapeutics, a clinical-stage biopharmaceutical company specializing in precision oncology, will present at the Jefferies Global Healthcare Conference on June 5, 2024. The company's CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat at 9:30 a.m. ET. The event will be webcast live and accessible via the company's investor relations page. The presentation will utilize Acrivon's proprietary AP3 platform, which identifies patients whose tumors are likely to respond to specific oncology treatments. A replay of the webcast will be available for 30 days.
Acrivon Therapeutics reported its first quarter 2024 financial results and business highlights on May 14, 2024. The company, which leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform for developing precision oncology medicines, made significant strides in its clinical and preclinical pipeline.
Key achievements include the validation of the AP3 platform's ACR-368 OncoSignature assay, demonstrating a 50% overall confirmed response rate in patients with ovarian and endometrial cancer. The company has also accelerated the IND timeline for ACR-2316, a new WEE1/PKMYT1 inhibitor, with clinical trials expected to begin in Q4 2024. Financially, Acrivon reported a net loss of $16.5 million for Q1 2024, compared to $12.8 million in Q1 2023. The company raised $130 million in a private placement, extending its cash runway into H2 2026.
FAQ
What is the current stock price of Acrivon Therapeutics (ACRV)?
What is the market cap of Acrivon Therapeutics (ACRV)?
What does Acrivon Therapeutics specialize in?
What is Acrivon's leading drug candidate?
What is the Acrivon Predictive Precision Proteomics (AP3) platform?
Has Acrivon received any regulatory designations for its drugs?
What recent achievements has Acrivon announced?
What is the status of Acrivon's ACR-2316 drug candidate?
How does the AP3 platform contribute to drug development?
What is the significance of the ACR-368 OncoSignature test?
How well-funded is Acrivon for its ongoing and future projects?
Where can investors find more information about Acrivon?
